FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

13 May 2024 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming May Conferences

09 May 2024 08:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

08 May 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

18 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

20 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 08:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

09 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET

31 Oct 2023 08:50:33 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

22 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 Sep 2023 16:30:00 By Nasdaq GlobeNewswire